WEST PHARMACEUTICAL SERVICES INC 8-K

What Happened

• West Pharmaceutical Services, Inc. (WST) announced that Michel Lagarde will become President and Chief Executive Officer effective August 31, 2026. Current CEO and Chair Eric M. Green informed the board on March 6, 2026 that he intends to retire once his successor is hired; he will resign from the board on the Start Date. Lead Independent Director Robert F. Friel will become Chair of the Board as of the Start Date. The company filed the employment agreement (signed May 31, 2026) and a press release in the Form 8‑K dated June 1, 2026.

Key Details

• Base salary: $1,175,000 annually, subject to periodic review beginning in 2027.
• Annual incentive: target equal to 125% of salary (target $1,468,750), prorated for 2026.
• 2026 long‑term incentive (prorated): total grant value $8,611,111 (target $10,000,000 prorated), awarded 50% PSUs / 25% RSUs / 25% options.
• One‑time inducement equity (maximum $10,000,000 total): sign‑on grant valued at $6,875,000 (same mix as above) plus matching grants tied to up to $2,500,000 of Mr. Lagarde’s stock purchases (max RSUs $1,250,000; max stock option value $1,875,000). Matching awards cliff‑vest at year 5; matching options have a 10‑year term.
• Severance: generally 12 months’ salary continuation and COBRA for involuntary termination without Cause or resignation for Good Reason (outside the 2‑year post‑change‑in‑control period). If termination occurs within two years after a change in control, severance includes a lump sum equal to 2x (salary + prior 3‑year average bonus), 36 months of certain benefits, and full vesting of outstanding LTI awards (subject to 280G cutback).
• Background: Mr. Lagarde, 52, is currently EVP & COO of Thermo Fisher Scientific, previously President & COO of Patheon, and joined the Board of Vertex Pharmaceuticals in 2023 (Chair, Audit & Finance Committee). The filing states no family ties or related‑party arrangements and no material related transactions to disclose.

Why It Matters

• Leadership change is material: a new CEO and board chair can affect company strategy, operations and investor expectations. The compensation package includes substantial equity and cash incentives that may increase near‑term executive compensation expense and lead to future equity dilution. Severance and change‑in‑control protections are in line with the prior CEO’s agreement and could affect post‑change governance and costs. Investors should note the effective date (Aug 31, 2026) and the disclosed pay and equity terms when assessing management continuity and potential shareholder impact.